Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

被引:0
|
作者
Sophie Mathais
Xavier Moisset
Bruno Pereira
Frédéric Taithe
Jonathan Ciron
Pierre Labauge
Cécile Dulau
David Laplaud
Jérôme De Seze
Jean Pelletier
Eric Berger
Christine Lebrun-Frenay
Giovanni Castelnovo
Gilles Edan
Gilles Defer
Patrick Vermersch
Bertrand Bourre
Jean-Philippe Camdessanche
Laurent Magy
Anne-Marie Guennoc
Guillaume Mathey
Thibault Moreau
Olivier Gout
Olivier Heinzlef
Elisabeth Maillart
Sandra Vukusic
Pierre Clavelou
机构
[1] CHU de Clermont-Ferrand,Department of Neurology
[2] Université Clermont Auvergne,Service de Neurologie & CIC015 INSERM
[3] INSERM,Department of Neurology and Clinical Investigation Center
[4] Neuro-Dol,APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques
[5] CHU de Toulouse,Department of Neurology
[6] CHU de Montpellier,CRCSEP Nice, Pasteur2 Hospital
[7] MS Unit,Department of Neurology
[8] University of Montpellier (MUSE),Department of Neurology
[9] University Bordeaux,Department of Neurology
[10] INSERM U1215,Department of Neurology
[11] Neurocentre Magendie,CRC SEP and Department of Neurology
[12] CHU de Bordeaux,Department of Neurology
[13] CIC Bordeaux CIC1401,Department of Neurology
[14] CHU de Nantes,Department of Neurology
[15] INSERM CR1064,Departement of Neurology
[16] CHU de Strasbourg,Department of Neurology
[17] INSERM 1434,Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro
[18] Service de Neurologie,Inflammation
[19] CHU de Besançon,Centre des Neurosciences de Lyon
[20] CHU de Nice,Faculté de Médecine Lyon Est
[21] UR2CA,undefined
[22] Nice Cote d’Azur University,undefined
[23] CHU de Nîmes,undefined
[24] CHU Pontchaillou,undefined
[25] CIC1414 INSERM,undefined
[26] CHU de la Côte de Nacre,undefined
[27] Univ. Lille,undefined
[28] INSERM UMR-S1172,undefined
[29] CHU Lille,undefined
[30] FHU Imminent,undefined
[31] CHU de Rouen / Rouen University Hospital,undefined
[32] CHU de Saint-Étienne,undefined
[33] Hôpital Nord,undefined
[34] CHU de Saint-Étienne,undefined
[35] Hôpital Nord,undefined
[36] CHU de Limoges,undefined
[37] Hôpital Dupuytren,undefined
[38] CHU de Tours,undefined
[39] Hôpital Bretonneau,undefined
[40] Nancy University Hospital,undefined
[41] Université de Lorraine,undefined
[42] CHU de Dijon,undefined
[43] Fondation Rotschild,undefined
[44] Hôpital de Poissy,undefined
[45] APHP,undefined
[46] Pitié-Salpêtrière Hospital,undefined
[47] Hôpital Neurologique Pierre Wertheimer,undefined
[48] Hospices Civils de Lyon,undefined
[49] Observatoire Français de la Sclérose en Plaques,undefined
[50] Université Claude Bernard Lyon 1,undefined
来源
Neurotherapeutics | 2021年 / 18卷
关键词
Progressive multiple sclerosis; Clinical trials observational study; Biotin; Relapse; Propensity score;
D O I
暂无
中图分类号
学科分类号
摘要
High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Several reports have suggested that HDB treatment may be associated with an increased risk of relapse. We aimed to determine whether HDB increases the risk of clinical relapse in PMS and describe the characteristics of the patients who experience it. We conducted a French, multicenter, retrospective study, comparing a group of PMS patients treated with HDB to a matched control group. Poisson regression was applied to model the specific statistical distribution of the annualized relapse rate (ARR). A propensity score (PS), based on the inverse probability of treatment weighting (IPTW), was used to adjust for indication bias and included the following variables: gender, primary PMS or not, age, EDSS, time since the last relapse, and co-prescription of a DMT. Two thousand six hundred twenty-eight patients treated with HDB and 654 controls were analyzed with a follow-up of 17 ± 8 months. Among them, 148 validated relapses were observed in the group treated with biotin and 38 in the control group (p = 0.62). After adjustment based on the PS, the ARR was 0.044 ± 0.23 for the biotin-treated group and 0.028 ± 0.16 for the control group (p = 0.18). The more relapses there were before biotin, the higher the risk of relapse during treatment, independently from the use of HDB. While the number of relapses reported for patients with no previous inflammatory activity receiving biotin has gradually increased, the present retrospective study is adequately powered to exclude an elevated risk of relapse for patients with PMS treated with HDB.
引用
收藏
页码:378 / 386
页数:8
相关论文
共 50 条
  • [1] Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
    Mathais, Sophie
    Moisset, Xavier
    Pereira, Bruno
    Taithe, Frederic
    Ciron, Jonathan
    Labauge, Pierre
    Dulau, Cecile
    Laplaud, David
    De Seze, Jerome
    Pelletier, Jean
    Berger, Eric
    Lebrun-Frenay, Christine
    Castelnovo, Giovanni
    Edan, Gilles
    Defer, Gilles
    Vermersch, Patrick
    Bourre, Bertrand
    Camdessanche, Jean-Philippe
    Magy, Laurent
    Guennoc, Anne-Marie
    Mathey, Guillaume
    Moreau, Thibault
    Gout, Olivier
    Heinzlef, Olivier
    Maillart, Elisabeth
    Vukusic, Sandra
    Clavelou, Pierre
    [J]. NEUROTHERAPEUTICS, 2021, 18 (01) : 378 - 386
  • [2] Frequency and description of relapses in a cohort of progressive multiple sclerosis patients treated with high dose biotin
    Liegey, J. S.
    Brochet, B.
    Moroso, A.
    Ruet, A.
    Ouallet, J. C.
    Louiset, P.
    Guerard, P.
    Deloire, M.
    Dulau, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 917 - 918
  • [3] The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis
    Goldschmidt, Carolyn H.
    Cohen, Jeffrey A.
    [J]. NEUROTHERAPEUTICS, 2020, 17 (03) : 968 - 970
  • [4] The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis
    Carolyn H. Goldschmidt
    Jeffrey A. Cohen
    [J]. Neurotherapeutics, 2020, 17 : 968 - 970
  • [5] Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis
    Granella, F.
    Tsantes, E.
    Siena, E.
    Curti, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 376 - 376
  • [6] Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin
    Maillart, Elisabeth
    Mochel, Fanny
    Acquaviva, Cecile
    Maisonobe, Thierry
    Stankoff, Bruno
    [J]. NEUROLOGY, 2019, 92 (22) : 1060 - 1062
  • [7] High Dose Biotin as Treatment for Progressive Multiple Sclerosis
    Birnbaum, Gary
    Stulc, Jessica
    Snyder, Tori M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 71 - 72
  • [8] High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice
    Couloume, Laura
    Barbin, Laetitia
    Leray, Emmanuelle
    Wiertlewski, Sandrine
    Le Page, Emmanuelle
    Kerbrat, Anne
    Ory, Solenn
    Le Port, Damien
    Edan, Gilles
    Laplaud, David-Axel
    Michel, Laure
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (14) : 1898 - 1906
  • [9] High-dose biotin in progressive multiple sclerosis: a prospective study of 178 patients in routine clinical practice
    Couloume, L.
    Barbin, L.
    Wiertlewski, S.
    Le Page, E.
    Kerbrat, A.
    Ory, S.
    Le Port, D.
    Edan, G.
    Laplaud, D. -A.
    Michel, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 529 - 530
  • [10] High dose biotin as treatment for progressive multiple sclerosis
    Birnbaum, Gary
    Stulc, Jessica
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 141 - 143